A Comparative Look at the Safety Profiles of Intravenous Iron Products Used in the Hemodialysis Population

Abstract

Spanish

French

OBJECTIVE:

To review clinical trials conducted in hemodialysis patients of the 4 intravenous iron products available in the US in an attempt to discern strengths and inferiorities between products and evaluate current safety data that can be used to assist the clinician in selecting the most appropriate agent.

DATA SOURCES:

Literature was accessed through PubMed (January 2000-October 2010). In some cases, reference citations from selected review articles were evaluated as well.

STUDY SELECTION AND DATA EXTRACTION:

Clinical trials published in the English language were selected using the search terms iron dextran, iron sucrose, sodium ferric gluconate, and ferumoxytol. Studies were further pared down to include only those enrolling hemodialysis patients.

DATA SYNTHESIS:

There are currently 4 intravenous iron formulations in the US used to treat iron-deficiency anemia in hemodialysis patients. Ferumoxytol has not yet been directly compared to the other 3 agents. Eight studies have been conducted in hemodialysis patients directly comparing iron dextran, iron sucrose, and/or sodium ferric gluconate. These studies were further categorized for evaluation based on iron products compared. Four studies directly compared iron dextran to iron sucrose, 1 study compared iron dextran to sodium ferric gluconate, 1 study compared iron sucrose to sodium ferric gluconate, and 2 studies compared all 3 agents. Of the 3 agents, iron dextran appears to have the least favorable safety profile, while iron sucrose appears most favorable.

CONCLUSIONS:

The newest intravenous iron product, ferumoxytol, has not been directly compared to the other 3 agents. Large well-controlled studies of these products specifically in the hemodialysis population would further help clinicians determine appropriate therapy. Iron sucrose appears to offer the most favorable safety profile when compared to iron dextran and sodium ferric gluconate in treating hemodialysis patients. Oxidative stress and hypersensitivity reactions are common problems encountered when administering intravenous iron.

Keywords

ferumoxytol hemodialysis iron dextran iron sucrose sodium ferric gluconate

Get full access to this article

View all access options for this article.

References

US Renal Data System. USRDS 2009 annual data report: Atlas of chronic kidney disease and end-stage renal disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2009.

KDOQI clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease: 2007 update of hemoglobin target. http://www.kidney.org/professionals/KDOQI/guidelines_anemiaUP/index.htm (accessed 2010 Jun 23).

KDOQI clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease. http://www.kidney.org/professionals/KDOQI/guidelines_anemia/index.htm (accessed 2010 Jun 23).

Hayat

Safety issues with intravenous iron products in the management of anemia in chronic kidney disease. Clin Med Res 2008; 6: 93–102. DOI 10.3121/cmr.2008.811.

Chertow

G M

Mason

P D

Vaage-Nilsen

Ahlmen

Update on adverse drug events associated with parenteral iron. Nephrol Dial Transplant 2006; 21: 378–82.

Product information. INFeD (iron dextran injection, USP). Morristown, NJ: Watson Pharma, Inc., September 2009.

Product information. Venofer (iron sucrose injection, USP). Shirley, NY: American Regent, Inc., October 2008.

Bailie

Clark

Lane

Hypersensitivity reactions and deaths associated with intravenous iron preparations. Nephrol Dial Transplant 2005; 20: 1443–9.

Product information. Ferrlecit (sodium ferric gluconate complex injection). Bridgewater, NJ: Sanofi-Aventis US LLC, January 2010.

10.

Product information. Feraheme (ferumoxytol injection). Lexington, MA: AMAG Pharmaceuticals Inc., June 2009.

11.

Provenzano

Schiller

Rao

Coyne

Brenner

Pereira

B J

. Ferumoxytol as an intravenous iron replacement therapy in hemodialysis patients. Clin J Am Soc Nephrol 2009; 4: 386–93. DOI 10.2215/CJN.02840608.

12.

Landry

Jacobs

P M

Davis

Shenouda

Bolton

W K

. Pharmacokinetic study of ferumoxytol: A new iron replacement therapy in normal subjects and hemodialysis patients. Am J Nephrol 2005; 25: 400–10. DOI 10.1159/000087212.

13.

Cohen

M H

Rieves

Pazdur

FDA report: Ferumoxytol for intravenous iron therapy in adult patients with chronic kidney disease. Am J Hematol 2010; 85: 315–9. DOI 10.1002/ajh.21656.

14.

Coyne

Ferumoxytol for treatment of iron deficiency anemia in patients with chronic kidney disease. Expert Opin Pharmacother 2009; 10: 2563–8.

15.

Section 9: Rx products and April 2010 updates. In: Drug topics red book. 113th ed. Montvale, NJ: Thomson Reuters, 2009.

16.

US Food and Drug Administration. http://www.accessdata.fda.gov/scripts/cder/drugsatfda/ (accessed 2010 Jul 30).

17.

Macdougall

I C

. Evolution of iv iron compounds over the last century. J Ren Care 2009; 35: 8–13.

18.

Zager

R A

Johnson

A C

Hanson

S Y

Wasse

Parenteral iron formulations: A comparative toxicologic analysis and mechanisms of cell injury. Am J Kidney Dis 2002; 40: 90–103. DOI 10.1053/ajkd.2002.33917.

19.

Malindretos

Sarafidis

P A

Rudenco

. Slow intravenous iron administration does not aggravate oxidative stress and inflammatory biomarkers during hemodialysis: A comparative study between iron sucrose and iron dextran. Am J Nephrol 2007; 27: 572–9. DOI 10.1159/000107928.

20.

Sav

Tokgoz

Sipahioglu

M H

. Is there a difference between the allergic potencies of the iron sucrose and low molecular weight iron dextran. Ren Fail 2007; 29: 423–6. DOI 10.1080/08860220701278208.

21.

Haddad

Abbadi

Marji

Use of iron sucrose in dialysis patients sensitive to iron dextran. Saudi J Kidney Dis Transpl 2009; 20: 208–11.

22.

Van Wyck

D B

Cavallo

Spinowitz

B S

. Safety and efficacy of iron sucrose in patients sensitive to iron dextran: North American clinical trial. Am J Kidney Dis 2000; 1: 88–97.

23.

Pai

A B

Boyd

A V

McQuade

C R

Harford

Norenberg

J P

Zager

P G

. Comparison of oxidative stress markers after intravenous administration of iron dextran, sodium ferric gluconate, and iron sucrose in patients undergoing hemodialysis. Pharmacotherapy 2007; 27: 343–50.

24.

Halliwell

Chirico

Lipid peroxidation: Its mechanisms, measurement, and significance. Am J Clin Nutr 1993; 57: S715–24.

25.

Michael

Coyne

D W

Fishbane

. Sodium ferric gluconate complex in hemodialysis patients: Adverse reactions compared to placebo and iron dextran. Kidney Int 2002; 61: 1830–9.

26.

Kosch

Bahner

Bettger

Matzkies

Teschner

Schaefer

A randomized, controlled, parallel-group trial on efficacy and safety of iron sucrose (Venofer) vs iron gluconate (Ferrlecit) in haemodialysis patients treated with rHuEpo. Nephrol Dial Transplant 2001; 16: 1239–44.

27.

Anirban

Kohli

H S

Jha

Gupta

K L

Sakhuja

The comparative safety of various intravenous iron preparations in chronic kidney disease patients. Ren Fail 2008; 30: 629–38. DOI 10.1080/08860220802134631.

28.

Rangel

Esposito

Carneiro

. Labile plasma iron generation after intravenous iron is time-dependent and transitory in patients undergoing chronic hemodialysis. Ther Apher Dial 2010; 14: 186–92. DOI 10.1111/j.1744-9987.2009.00786.x.